signature of four (RP11-326A19.5, RP4-706A16.3, RPL7AP28, RPL11-551L14.1) pseudogenes for osteosarcoma, which is a promising independent survival predictor and serves as an important biomarker for clinical treatment of osteosarcoma to improve patient management. This evidence concerns the gene RPL11 and osteosarcoma.